Addex Therapeutics Ltd (ADXN) |
| 8.8 0.57 (6.93%) 01-13 16:00 |
| Open: | 8.6414 |
| High: | 10.43 |
| Low: | 7 |
| Volume: | 83,144 |
| Market Cap: | 6(M) |
| PE Ratio: | -0.98 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 12.18 |
| Resistance 1: | 10.43 |
| Pivot price: | 8.04 |
| Support 1: | 8.31 |
| Support 2: | 7.00 |
| 52w High: | 12.05 |
| 52w Low: | 6.51 |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Financials
| EPS | -2460000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -7.143 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -1.00 |
| Return on Assets (ttm) | 403.6 |
| Return on Equity (ttm) | -15.9 |
Company news
Wed, 07 Jan 2026
Addex Therapeutics (ADXN) Advances NTX-253 into Clinical Trials for Schizophrenia - GuruFocus
Wed, 07 Jan 2026
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia - marketscreener.com
Mon, 05 Jan 2026
Avoiding Lag: Real-Time Signals in (ADXN) Movement - Stock Traders Daily
Thu, 11 Dec 2025
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. - The Manila Times
Thu, 04 Dec 2025
Earnings Scheduled For December 4, 2025 - Addex Therapeutics (NASDAQ:ADXN), Argan (NYSE:AGX) - Benzinga
Thu, 04 Dec 2025
Earnings call transcript: Addex Therapeutics Q3 2025 sees stock dip post-earnings - Investing.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
